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Balanced chromosomal abnormalities (BCAs) rep-
resent a relatively untapped reservoir of single-
gene disruptions in neurodevelopmental disorders
(NDDs). We sequenced BCAs in patients with
autism or related NDDs, revealing disruption of 33
loci in four general categories: (1) genes previously
associated with abnormal neurodevelopment (e.g.,
AUTS2, FOXP1, and CDKL5), (2) single-gene con-
tributors to microdeletion syndromes (MBD5,
SATB2, EHMT1, and SNURF-SNRPN), (3) novel
risk loci (e.g., CHD8, KIRREL3, and ZNF507), and(4) genes associated with later-onset psychiatric
disorders (e.g., TCF4, ZNF804A, PDE10A, GRIN2B,
and ANK3). We also discovered among neurodeve-
lopmental cases a profoundly increased burden of
copy-number variants from these 33 loci and a
significant enrichment of polygenic risk alleles
from genome-wide association studies of autism
and schizophrenia. Our findings suggest a polygenic
risk model of autism and reveal that some neurode-
velopmental genes are sensitive to perturbation by
multiple mutational mechanisms, leading to variable
phenotypic outcomes that manifest at different life
stages.Cell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc. 525
INTRODUCTION
Mounting evidence indicates that genomic structural variants
(SVs) collectively play a substantial role in susceptibility to autism
spectrum disorders (ASDs) and other neurodevelopmental
disorders (NDDs). However, the near ubiquitous use of chromo-
somal microarrays in research and clinical diagnostics has
limited the assessment of those classes of SV that do not involve
large gains and losses of genetic material, such as inversions,
excision/insertions, and translocations, which together consti-
tute balanced chromosomal abnormalities (BCAs). These events
are typically defined clinically at karyotypic resolution and impli-
cate only broad chromosomal regions, without the gene-level
sequence specificity that would permit informative interpreta-
tion. Even in the research setting, there is often a failure to
consider or assess BCAs, consequently bypassing a meaningful
proportion of subjects with genetic events that maymark a single
locus of potentially large effect. These balanced events offer a
unique route, complementary to conventional approaches, for
identifying individual genes or functional sequences that con-
tribute to otherwise genetically complex human disorders. At
cytogenetic resolution, the estimated frequency of BCAs in
ASD is 1.3% (Marshall et al., 2008), an approximately 6-fold
increase over that observed in more than 10,000 reproductively
normal controls (Ravel et al., 2006). This ratio is almost certainly
a lower bound for relative risk, given the resolution of available
techniques and the inability to survey submicroscopic balanced
alterations. Thus, BCAs have a meaningful impact in ASD and
represent a fertile area for high-resolution study to identify func-
tional sequences that contribute to human neurodevelopment.
We previously described innovations in the molecular
approach to massively parallel sequencing and tailored bioinfor-
matics applicable to the rapid, high-resolution discovery of
chromosomal rearrangement breakpoints (Talkowski et al.,
2011a). These and conceptually similar methods were recently
used to derive potential mechanisms of chromosomal rear-
rangements in B-lymphocytes (Chiarle et al., 2011; Klein et al.,
2011), to delineate complex chromosomal rearrangements and
chromothripsis in cancer cells (Stephens et al., 2011), and to
document balanced chromothripsis and predominant nonho-
mologous repair in the human germline and transgenic animals
(Chiang et al., 2012). Here, with nucleotide resolution, we pre-
cisely characterize karyotypically defined human constitutional
chromosomal rearrangements: 36 de novo BCAs and two in-
herited rearrangements that were transmitted from an affected
parent. The results of our sequencing analyses, coupled with
extensive secondary genomics support, indicate that disruption
of genes from awide range of biological pathways can contribute
to ASD. In many instances, the same genes also confer risk,
sometimes via different mutational mechanisms, to a range of
NDDs and psychiatric disorders in both children and adults.
RESULTS
Identification of Genes Contributing
to Neurodevelopmental Abnormalities
Using a series of previously developed next-generation
sequencing techniques ranging from high-depth whole-genome526 Cell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc.sequencing to a targeted capture of breakpoints approach (Talk-
owski et al., 2011a), we delineated BCAs in 38 subjects with
neurodevelopmental abnormalities; these subjects include two
monozygotic twin pairs (36 independent probands). All harbored
a BCA that appeared balanced at karyotypic resolution and was
interpreted as pathogenic by the clinical geneticist; 36 aberra-
tions arose de novo, whereas two alterations were transmitted
from an affected parent and thus segregated with the pheno-
type. Extensive clinical data were collected for all subjects and
affected parents, as described in the Supplemental Information
(available online). If a structured diagnostic interview was per-
formed, or a patient was formally diagnosed with autism or an
ASD by the referring clinician according to DSM-IV criteria,
they are referred to herein as ASD (50% of subjects); otherwise
the disorder was classified as NDD, although many such
subjects also displayed clinical features consistent with ASD.
For complete clinical information for each subject and each
BCA breakpoint, confirmed by PCR and capillary sequencing,
see Data S1: Phenotypic and Sequencing Information on Indi-
vidual Patients. Previously performed genetic testing was also
obtained, and all results were unremarkable with 244,000 or 1
million feature array comparative genomic hybridization
(aCGH) unless otherwise described in the Supplemental
Information.
This BCA sequencing approach uncovered genes that con-
formed to four general classifications, and there was meaningful
overlap between categories: (1) genes previously implicated in
ASD or NDD and confirmed here by their heterozygous inactiva-
tion, (2) genes discovered to be single-locus contributors to
microdeletion syndromes, (3) genes not previously implicated
individually in ASD or NDD, and (4) genes previously associated
with adolescent- and adult-onset psychiatric disorders by
common variant genome-wide association studies (GWASs) or
other approaches; all but three of these represent novel ASD
or NDD loci. Alterations in gene expression were also assessed
for all subjects where a lymphoblastoid cell line could be
obtained (33 of 38 subjects; Figure S1). If a gene was not directly
disrupted, positional effects on expression were evaluated for
genes in proximity to the breakpoint. All genes and sequences
disrupted by BCAs are presented in Table S1 along with results
of mRNA expression studies, whereas the subset of genes,
supported by secondary analyses, is presented below and in
Table 1.
Convergent Data from Molecular Diagnostics
Although the presence of a BCA is conservatively associated
with an 6-fold increased risk of ASD, any individual BCA is
rare and generally nonrecurrent, precluding assessment of false
discovery by replication; consequently, we analyzed copy-
number variants (CNVs) to test whether specific locus hemi-
zygosity contributes to genetic risk of neurodevelopmental
abnormalities. We curated and analyzed a large collection of
33,573 cases from molecular diagnostic facilities and identified
that subset of cases referred for a variety of neurodevelopmental
abnormalities (n = 19,556), as well as that comprising cases
without a referral indication of NDD (n = 14,017). We also
surveyed CNV data from 13,991 controls screened for absence
of a reported developmental or psychiatric phenotype. Although
Table 1. Genes Disrupted by Chromosomal Rearrangementsa
Cat ID Dx ChrA ChrB Disrupted Fisher’s Exact pb Function
1 DGAP201 ASD 7q11.22 7q36.3 AUTS2 5.6 3 104 unknown
1 and 4 NDR27031 NDD 3q13.32 18q21.2 TCF4 6.2 3 104 transcription factor
1 DGAP093 NDD Xp22.13 19p13.3 CDKL5 7.2 3 102 protein kinase
1 DGAP157 NDD 3p13 10q21.2 FOXP1 4.5 3 102 transcription factor
1 and 4 NDR25941 ASD 12p13.1 12q21.31 GRIN2B 7.9 3 102 glutamate receptor
1 DGAP189 NDD 11p13 12p12.1 SOX5 8.4 3 102 transcription factor in embryonic development
2 DGAP232 ASD 9p11.2 15q11.2 SNURF-SNRPN 1.1 3 1013 genomic imprinting in angelman – pws region
2 and 4 DGAP155 ASD 9q34.3 11p11.2 EHMT1 3.3 3 107 histone methyltransferase
2 DGAP142 ASD 2q23.1 22q13 MBD5 3.1 3 105 methylation binding
2 DGAP211 ASD 2q33.1 6q16.3 SATB2 1.1 3 103 transcriptional regulation and chromatin remodeling
3 DGAP148 NDD Xp11.4 11q24.2 KIRREL3 1.6 3 104 cell adhesion
3 DGAP154 NDD Xq22 17p13.3 SMG6 5.9 3 104 nonsense-mediated decay
3 NDR26867 ASD 3q25.31 14q11.2 CHD8 2.4 3 102 chromatin remodeling
3 DGAP125 NDD 7q32.1 19q13.11 ZNF507 8.0 3 102 zinc finger
3 DGAP132c NDD 5q12.2 7q21.3 PON3 1.5 3 101 lactonase
3 AC02-0053 ASD 6q16.1 9q21.13 GNA14 2.7 3 101 g-protein signaling
3 DGAP131 NDD 1p22.3 5q33 ZNHIT6 2.7 3 101 zinc finger protein
3 DGAP193 ASD 2p22.3 2q31.3 SPAST 2.7 3 101 membrane trafficking
3 and 4 DGAP143 NDD 6q22.1 6q27 PDE10A 5.2 3 103 phosphodiesterase
3 and 4 DGAP171 NDD 17p13.2 18p11.21 C18orf1 3.2 3 102 unknown
3 and 4 DGAP180c NDD 2q32 11q14 ZNF804A 4.7 3 102 zinc finger protein
The following abbreviations are used: Cat, disruption category; Dx, diagnosis; ASD, autism spectrum disorder; NDD, other neurodevelopmental
disorders; ChrA and ChrB = sequenced chromosomal sub-band containing the BCA. For the entire data set used to generate this table, see also
Tables S1, S2, and S3.
aBCA-disrupted genes individually implicated by case-control CNV burden at uncorrected p < 0.10 or by a minimum of 3 CNVs in cases with none in
controls are provided. See Table S1 and Supplemental Information for all subjects and phenotypes and Table S2 for CNV counts on all subjects.
bFisher’s exact test p value from comparison of CNV burden between NDD cases and controls.
cBCA inherited from similarly affected parent.almost 25% of the 19,556 cases with neurodevelopmental
abnormalities were referred for testing with an indication of
autism or ASD, we did not have direct access to clinical records
to confirm this diagnosis so we conservatively describe these
cases by using the broader term NDD. Our findings indicate
that genes disrupted by BCAs in ASD individuals frequently
show increased CNV burden across the diagnostic cases
referred for ASD as well as those referred for other neurodeve-
lopmental abnormalities, suggesting that the genes discovered
can contribute to phenotypic outcomes that are not constrained
by ASD diagnostic criteria.
An example of the convergent genomic information collected
in this study is depicted in Figure 1; sequencing of monozygotic
twins with extensive clinical information revealed a translocation
disrupting TCF4, a gene previously implicated in both Pitt-
Hopkins syndrome and schizophrenia, with concomitantly
decreased mRNA expression in both subjects and a significant
impact of CNV burden across the clinical diagnostic samples
(14 case CNVs, 0 control CNVs; p = 0.0006). Additional follow-
up analyses revealed a significant GWAS signal from common
SNPs at TCF4 in both autism and schizophrenia (see analyses
of polygenic risk from GWAS studies below and in Table S2).
Across all loci disrupted by BCAs, a dramatic increase in over-
all CNV burden was observed in cases compared to controls(CNV burden across 33 loci: p = 2.07 3 1047, odds ratio
[OR] = 5.12, 95%CI = 3.92–6.79), and this result remained robust
to subset analyses and 1 million random simulations to assess
empirical significance (see Table S2 for CNV results and
Extended Experimental Procedures for analysis details).
Comparison of the NDD cases to the 14,017 diagnostic cases
referred for a primary indication other than NDD and analyzed
on identical platforms also showed an increased CNV burden
across these genes (p = 1.83 105), a result that again exceeded
the significance of 1 million random simulations despite the
previously established enrichment of large CNVs in the latter
cases, which we replicate here. Notably, restricting CNV anal-
yses to only those genes disrupted by a BCA in an individual
with a confirmed diagnosis of ASD was also highly significant
(p = 2.76 3 1028; Table 1). Individually, increased CNV burden
was nominally significant for 14 of the genes in this study, with
three nonsignificant trends (p < 0.10), whereas five additional
genes were disrupted by CNVs in three or more independent
cases but never altered in controls. For the latter, the rarity of
dosage alteration in cases and absence of alterations in controls
limit statistical power but are consistent with a strong deleterious
effect. In each category discussed further below, the genes sup-
ported by secondary CNVs are briefly mentioned and presented
in Table 1, whereas the full list of genes disrupted by BCAs isCell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc. 527
Figure 1. Convergent Genomic Evidence Implicates TCF4 in Neurodevelopment
(A) A t(3;18)(q13.32;q21.2) translocation was sequenced with our custom jumping library protocol in monozygotic twin boys with multiple developmental
abnormalities, directly disrupting TCF4 in intron 8, a gene previously associated with Pitt-Hopkins syndrome (PHS) by mutation analysis and with schizophrenia
by GWAS.
(B) Analysis of CNVs revealed disruption of coding and noncoding exons in 14 independent CNVs among 19,556 NDD cases compared to no CNVs observed in
13,991 controls (p = 0.0006), implicating hemizygosity of TCF4 as a highly penetrant locus in NDD, PHS, and ASD (see also Table S2 and Rosenfeld et al., 2009b).
(C) Reduced mRNA expression of TCF4was detected in both cases from EBV-transformed lymphoblastoid cell lines compared to two gender-matched controls
with two independent primers spanning exons 16-17 and exons 18-19. For related supplemental data, see also Figures S1 and S2, Tables S1 and S2, and Data
S1: Phenotypic and Sequencing Information on Individual Patients.delineated in Table S1 and discussed in the Supplemental
Information.
Category 1: Balanced Alterations Confirming Loci
Previously Implicated in Neurodevelopment
The power of sequencing BCAs as a discovery tool for loci
contributing to disease etiology is illustrated in our independent
identification of several genes previously suggested as candi-
dates in ASD or NDD. We found direct disruption of AUTS2
and CDKL5, two established neurodevelopmental loci (Bakkalo-
glu et al., 2008; Sultana et al., 2002). We also found disruption of
the fork-head transcription factor FOXP1 and the glutamate
receptor GRIN2B, genes identified from de novo mutations in
ASD by an exome-sequencing study (O’Roak et al., 2011). We
also uncovered disruptions in TCF4, a gene mutated in Pitt-Hop-
kins syndrome as well as other genes implicated by CNV anal-
ysis of an autism cohort (the transcription factor SOX5 and the
dystrophin regulator SNTG2) (Rosenfeld et al., 2010). Consistent
with their status as previously recognized contributors to neuro-
development, the collective CNV burden of these genes is sig-
nificant (p = 7.74 3 1020; OR = 3.6) (Table 2).
Category 2: Individual Genes Contributing to
Microdeletion Syndromes
Microdeletion syndromes, which contribute to neurodevelop-
mental and psychiatric disorders, typically involve hemizygosity528 Cell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc.of large genomic regions where the difficulty of defining specific
genes responsible for core phenotypes has been an obstacle for
clinical genetics, predictive diagnostics, and the study of disease
pathogenesis. BCA sequencing in three ASD subjects pin-
pointed three individual gene contributors to microdeletion
syndromes, each of which is involved in transcriptional and/or
epigenetic regulation, in the 2q23.1, 2q33.1, and 9q34.3 micro-
deletion syndrome regions, respectively. In 2q23.1, a transloca-
tion disrupted MBD5, a member of the methyl-CpG binding
domain protein family defined by a highly conserved methyl
binding domain and including MeCP2, a causal locus in Rett
syndrome. An international consortium follow-up study recently
found 65 structural variations spanning the 2q23.1 microdeletion
region in cases with syndromic features, including ASD,
seizures, and intellectual disability, establishing MBD5 as a
necessary, sufficient, and predictive locus for a majority of the
phenotypic features of the 2q23.1microdeletion syndrome (Talk-
owski et al., 2011b). In the 2q33.1 and 9q34.3 regions, we
respectively identified disruption of SATB2, a gene involved in
transcriptional regulation and chromatin remodeling (Rosenfeld
et al., 2009a), and of EHMT1, encoding a histone methyltransfer-
ase (Kleefstra et al., 2006). In a fourth region (15q11-13), the
nested genes SNURF-SNRPN were disrupted at 15q11.2 in
a subject with ASD and multiple developmental abnormalities,
including sensory integration disorder, but without Angelman
or Prader-Willi syndromes, both of which result from imprinting
Table 2. Analysis of Copy-Number Variants in Independent
Samples
Gene
Categories
NDD
Counta
Control
Counta p Value OR 95% CI
All Genes 443 63 2.1 3 1047 5.1 3.9–6.8
Category 1 114 23 7.7 3 1020 3.6 2.3–5.9
Category 2 169 12 1.6 3 1026 10.2 5.7–20.1
Category 3 160 28 2.2 3 1015 4.1 2.7–6.4
Category 4 111 12 5.1 3 1015 6.7 3.7–13.3
Categories
1, 3, and 4
274 51 5.2 3 1024 3.9 2.9–5.3
All Genes = all 33 loci disrupted by BCAs and included in the CNV
analyses. Categories 1, 3, and 4 = analyses of all genes not localized to
microdeletion syndromes known to be associated with increased CNV
burden. See Table S2 for all genes in each category.
aCounts of CNVs from 19,556 NDD cases and 13,991 controls.within the region. Our data argue for increased resolution and
interpretation from molecular diagnostic testing of regional
disorders, particularly for loci in which individual gene disrup-
tions can yield phenotypes that are similar to or indistinguishable
from that defining the syndrome. Given their localization to syn-
dromic regions, it is not surprising that CNV analysis of genes
in this category reflected a strong impact in neurodevelopment
(p = 1.64 3 1026; OR = 10.2) (Table 2 and Figure 3).
Category 3: Novel Genes Conferring Risk to Autism
and Neurodevelopment
BCA sequencing yielded 22 novel ASD/NDD candidate genes
that, like the genes in categories 1 and 2, are also likely to
contribute to the neurodevelopmental phenotype in the corre-
sponding subjects. The collective increase in CNV burden for
these candidates was highly significant (p = 2.21 3 1015,
OR = 4.1) (Table 2).
The most significant individual genes are two loci localized to
previously identified genomic disorder regions (KIRREL3 and
SMG6) and one encoding a DNA helicase (CHD8). Similar to
the category 2 genes, we observed dysregulation by BCA and
secondary CNV support for novel genes in regions associated
with classic terminal deletion disorders: KIRREL3 in 11q24.1
(Jacobsen syndrome) and SMG6 in 17p13.3 (Miller-Dieker
syndrome). KIRREL3 encodes a cell adhesion molecule of the
immunoglobulin family expressed in developing and adult brain
of mouse and developing sensory pathways (Morikawa et al.,
2007; Serizawa et al., 2006; Tamura et al., 2005). The locus
was disrupted by a BCA 39.6 kb upstream of the mRNA coding
region that altered both mRNA and protein levels (Table 1 and
Figure S2). Disruption of SMG6 nominates nonsense-mediated
decay as another pathway in ASD and NDD, but not necessarily
in the lissencephaly phenotype commonly seen in Miller-Dieker
syndrome (see Supplemental Information and Figure S3).
CHD8 encodes a DNA helicase that remodels chromatin struc-
ture (Thompson et al., 2008). Although it has never been individ-
ually linked to a human disorder, it represents a strong autism
and NDD candidate locus. It was disrupted by a BCA in a subject
diagnosed with ASD (Table 1 and Data S1: Phenotypic and
Sequencing Information on Individual Patients), was supportedby our CNV analyses (Table S2, see also genes sensitive to
dosage dysregulation section below), and was among the loci
within the minimal region of overlap from previous analyses of
de novo microdeletions (Zahir et al., 2007). CHD8 is a transcrip-
tional repressor that also interacts with genes implicated in NDD
such as CHD7, a causal locus in CHARGE syndrome. (Batsukh
et al., 2010; Nishiyama et al., 2009; Rodrı´guez-Paredes et al.,
2009).
Additionally, in seven subjects no annotated gene was disrup-
ted but several expressed sequence tags (ESTs), conserved
sequences, and regions with predicted regulatory effects were
impacted by breakpoints (Table S1), suggesting that BCAs
may also provide a novel entre´e into such regions. In these
subjects, we considered both loci in proximity to the breakpoint
for positional effects (e.g., KIRREL3), as well as disrupted but
functionally unannotated sequences themselves, such as the
highly conserved 6q16.3 sequence of unknown function disrup-
ted by a BCA in an ASD subject (denoted as ‘‘High Cons’’ in
Table S1) and the noncoding RNA LOC401324.
Category 4: Neurodevelopmental Loci Associated with
Risk that Crosses Traditional Diagnostic Boundaries
A remarkable number of genes implicated in ASD or NDD by
single-gene disruption from BCAs in our study have also been
recently associated with a spectrum of developmental, psychi-
atric, and behavioral phenotypes by other strategies, such as
GWAS and mutation screening, including TCF4 (Pitt-Hopkins
syndrome, intellectual disability, schizophrenia) (Amiel et al.,
2007; Blake et al., 2010; Rosenfeld et al., 2009b), GRIN2B
(schizophrenia, bipolar disorder, and neurodevelopment) (En-
dele et al., 2010), EHMT1 (schizophrenia) (Kirov et al., 2012),
and four novel neurodevelopmental genes that overlap with
category 3: ZNF804A (schizophrenia, psychosis, and cognitive
function) (O’Donovan et al., 2008; Walters et al., 2010), ANK3
(bipolar disorder and schizophrenia) (Ferreira et al., 2008; Wil-
liams et al., 2011), C18orf1 (schizophrenia) (Meerabux et al.,
2009), and PDE10A (schizophrenia) (Kehler and Nielsen, 2011).
All loci with the exception of ANK3 are supported by secondary
CNV analyses (Table 1). Of these category 4 candidates not
previously associated with ASD or NDD, only PDE10A has an
established function, encoding a phosphodiesterase suggested
as a biological candidate in schizophrenia due to its high tissue-
specific expression in the caudate nucleus. Specific PDE10A
inhibitors provide a potential therapeutic approach to schizo-
phrenia due to their regulation of cAMP and cGMP, thereby
altering dopamine D1 and D2 receptor activity (Kehler and Niel-
sen, 2011; Lakics et al., 2010).
Genes in this category appear to contribute to pleiotropic
effects ranging from early-onset autism and intellectual disability
to adult-onset psychosis, often through different mutational
mechanisms. Several were previously associated with psychi-
atric disorders by unbiased GWAS and/or by candidate gene
studies of common variants, which are thought to reflect a
more subtle effect on gene regulation than the outright inactiva-
tion caused by the BCA disruption. One compelling example
of different mutational mechanisms is TCF4, where rare
mutations are recognized as causing NDD, sometimes with
a diagnosis of Pitt-Hopkins syndrome, but common TCF4Cell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc. 529
Figure 2. Genes Disrupted by Chromosomal Abnormalities Confer
Risk across Diagnostic Groups
All genes disrupted by a BCA and analyzed in the CNV analyses are shown.
Although all genes are implicated in ASD or NDD by BCA disruption in this
study, some loci also represented single-gene contributors to previously
recognized genomic disorder (GD) regions (three microdeletion syndromes,
two terminal deletion syndromes, and one duplication syndrome). There were
also genes discovered in ASD or NDD in this study that had been previously
linked to adolescent- or adult-onset neuropsychiatric disorders (NPD) by
common variation association studies. The asterisk (*) denotes a gene not
previously implicated in ASD or NDD (category 3). See also Table 1 and Table
S2 for CNV and GWAS support for each locus.variation has recently emerged as a significant risk factor for
schizophrenia. Taken together, our findings support the long-
hypothesized notion of a neurodevelopmental component to
adult-onset neuropsychiatric disorders such as schizophrenia
(Murray and Lewis, 1987; Owen et al., 2011; Weinberger,
1986). However, our data extend this hypothesis to suggest
that differing mutational impact on the same sets of genes
constitutes a significant overlap in the genetic etiology of autism,
schizophrenia, psychosis, bipolar disorder, and intellectual
disability, comprising at least a subset of the total genetic vari-
ance for each of these disorders. The collective CNV burden
for these genes decisively supports the fundamental hypothesis
that some psychiatric disease-associated genes are important in
neurodevelopment (p = 5.1 3 1015; OR = 6.7) (Table 2).
Polygenic Risk from Genome-wide Association Studies
Our identification of genes disrupted by BCA in ASD or NDDwith
an increased CNV burden among diagnostic cases with neuro-
developmental abnormalities suggests that these are relatively
penetrant alterations in human development, consistent with
polygenic risk factors of modest to large effect. However, the
discovery of the genes in category 4 suggests that for some
loci, an accumulation of subtle genetic effects associated with
common polymorphisms could have a pleiotropic impact across
a spectrum of early childhood and adult-onset psychiatric disor-
ders. To test this hypothesis, we performed gene-set enrichment
analyses in data sets from GWASs of autism and schizophrenia
(Ripke et al., 2011; Wang et al., 2009; Weiss et al., 2009) by using530 Cell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc.an established method in which each linkage disequilibrium
block across the genome is scored with the maximum Z score
achieved in the block (Rossin et al., 2011). Analysis of an initial
autism study revealed a highly significant enrichment of risk
alleles across the gene set (empirical p = 0.0018), a result that
persisted in the second GWAS of autism (p = 0.068). Moreover,
we discovered a significant enrichment of associated alleles
from the largest GWAS meta-analysis of schizophrenia to date
(empirical p = 0.0009). Struck by these results, we evaluated
the potential for any unforeseen confounding variables by per-
forming identical enrichment analyses in phenotype-permuted
data sets from the meta-analysis of schizophrenia and autism
studies (p = 0.444 and p = 0.518, respectively), in a well-powered
GWAS study of Crohn’s disease (p = 0.819) (Franke et al., 2010),
and from GWAS data for seven other unrelated traits (p values
ranged from p = 0.06 to p = 0.917, fitting nicely to the expected
null distribution). These data indicate an unusually strong
enrichment of subtle effects from common polygenic risk
loci in autism and schizophrenia among the genes identified by
our BCA sequencing and further support the hypothesis that
diverse mutational mechanisms at these loci can confer pleio-
tropic effects across conventional diagnostic classifications
(Figure 2).
Genes Sensitive to Dosage Dysregulation
The finding that some genes associated with ASD or NDD due
to inactivation of one allele may also contribute to abnormal
phenotypes when more subtly disrupted suggests that some
ASD or NDD genes require tight control of their expression for
appropriate neurodevelopmental function. In such circum-
stances, disruption by increased dosage might also produce
anNDD phenotype. This is highlighted inmore detailed examina-
tion of the CNV analyses presented in Figures 1, 3, and 4, which
indicate that for some genes, the CNV data predict that both
deletion and duplication are risk factors for abnormal neurode-
velopment, whereas for other loci the mechanism of disruption
appears to be dosage specific. For example, previously estab-
lished NDD risk loci (TCF4, Figure 1; SATB2 andMBD5, Figure 3)
almost exclusively display deletion among the CNV cases,
clearly supporting a similar mechanism of dysregulation to that
seen for the BCA disruption. This is also true for NDD candidates
such as PDE10A and KIRREL3. However, there are a number
of genes similar to the three instances shown here for which
CNV analysis supported genetic risk from both deletion and
duplication, approaching a near 50:50 balance, including two
well-established loci (AUTS2 and CDKL5) (Figure 4A and Table
S3). Interestingly, CNV analysis also supported genetic risk pre-
dominantly resulting from duplication of a locus (e.g., CHD8,
GRIN2B, and FOXP1, Figure 4B), suggesting similar phenotypic
outcomes from both dosage increase and heterozygous inacti-
vation by BCA disruption, as in this study, or de novo mutations
in a previous study (for GRIN2B and FOXP1) (O’Roak et al.,
2011). These data build upon previous findings in recurrent
rearrangement regions, such as the common recurrent
16p11.2 microdeletion/microduplication (Weiss et al., 2008),
where both deletion and duplication increase risk for autism to
different degrees and have disparate impacts (including recip-
rocal phenotypes) for other disorders and physiological traits.
Figure 3. Disruption of Individual Genes in Micro-
deletion Syndromes Regions
(A–C) Gene-specific view of sequenced BCAs and
CNVs implicating individual genes involved in transcrip-
tional or epigenetic regulation and localized to previously
described microdeletion syndromes, each of which
implicates a single gene by the combined BCA and CNV
analyses. Haploinsufficiency of mRNA was confirmed for
each gene (Figure S1). A breakpoint disrupting a two-gene
locus (SNURF and SNRPN) was detected in a fourth
microdeletion syndrome, 15q11-13 (not shown). Red bars
indicate copy loss, blue bars are copy gains, and striped
bars are gene-specific alterations. Green bars represent
‘‘Other’’ alterations (balanced or unbalanced trans-
location, inversion, or complex alteration involving both
deletion and duplication). The bar at the top provides the
count of gains and losses that extend beyond the window
and is color coded to reflect the relative proportion of each
variant type. Confidence intervals provide the distance
to the next probe without a detected dosage imbalance.
A single RefSeq transcript is provided. Breakpoint
sequence from each derivative is provided with text color
coded by originating chromosome or nontemplated in-
serted sequence in gray. A subset of the SATB2 patients
included here were previously reported by Rosenfeld et al.
(2009), and all cases reported here forMBD5, as well as 44
additional structural variants, are reported in a follow-up
consortium study (Talkowski et al., 2011b). See also Table
S3 and Figure S3.The clear distinction between neurodevelopmental loci associ-
ated primarily with deletion or duplication and those displaying
similarly abnormal neurodevelopment from either event empha-Cell 149sizes the need for detailed experimental annota-
tion of the genome with respect to dosage-
sensitive loci and phenotypic prediction.
Disrupted Genes Do Not Converge on
a Single Pathway in Neurodevelopment
The genomics approach in this study enabled
direct interpretation of locus specificity for
further downstream analyses. We evaluated
the networks in which these genes may partici-
pate and whether any biological pathways
emerged as significantly enriched for genes
disrupted by these BCAs. A qualitative network
analysis based on interactions from PubMed
abstracts and the use of a natural language
processing algorithm identified a network of
429 interacting genes (Figure 5 and Figure S4).
Fourteen of the original genes, many of which
are involved in transcriptional regulation, were
found to interact indirectly in a large, intercon-
nected network, and TCF4, SNRPN, CHD8,
and GTF2F1 were confirmed as interacting
partners of the RNA Polymerase II complex.
Analysis of gene ontology (GO) terms found
enrichment of transcription factors, phospho-
proteins, and protein heterodimerization activity
(p < 0.005). A quantitative network assessmentdid not find statistically significant first- or second-order interac-
tions compared to chance expectations (given the size and
composition of the given networks). The nominally significant, 525–537, April 27, 2012 ª2012 Elsevier Inc. 531
Figure 4. Genes Sensitive to Dosage Dysregulation
Provided is an example of genes illustrated by this study that appear to be sensitive to a spectrum of mutational mechanisms reciprocally altering their gene
dosage. In Figures 1 and 2 are examples of genes such as TCF4 and SATB2 that are disrupted exclusively by deletions.
(A) Genes sensitive to dosage dysregulation from which both deletion and duplication appear to confer risk for similar phenotypes (AUTS2, CDKL5, C18orf1).
(B) Three loci, FOXP1,GRIN2B, and CHD8, are recognized for duplication of the locus as the predominant mutational mechanism, yet all three loci are implicated
by heterozygous inactivation from BCA disruption in this study. Two of these genes, FOXP1 andGRIN2B are also supported by de novomutation in ASD families
(O’Roak et al., 2011). CHD8 is a completely novel candidate not previously implicated in ASD or any human abnormality. These data suggest annotation of the
human genome is insufficient to reliably predict the impact of various mutational mechanisms of specific loci involved in neurodevelopment. See also Table S3.networks (statistical enrichment of pathways at p < 0.05)
included shared interactions between SNTG2, UTRN, GNA14,
and CDKRAP2 (p = 0.01) as well as KCND2 and GRIN2B (p =
0.03) (Figure S4). The SNURF-SNRPN complex was nominally532 Cell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc.significant in both analyses and in an assessment of physical
interactions (Supplemental Information). No results were sig-
nificant after correction for multiple testing. There was also
no convergence on one or a few pathways involved in
Figure 5. Network Analysis of Genes Implicated in Autism or Neurodevelopment in This Study
A large network of genes disrupted by BCAs in this study are connected by first-, second-, or higher-order interactions. No networks were significantly enriched
for genes disrupted by BCAs after correction for multiple comparisons, though a number of loci have limited functional annotation available or remain of unknown
function. See also Figure S4.neurodevelopment, probably a reflection of the modest number
of genes studied and the unknown function of many of the novel
genes. These results could also signify that interaction of a
diverse range of functional networks at many levels is critical
to normal human neurodevelopment and that there is ample
opportunity for genetic lesions to disrupt different functional
pathways while still leading to similar neurodevelopmental
outcomes.
DISCUSSION
Direct sequencing of BCA breakpoints, followed by targeted
assessment ofmolecular diagnosticCNVfindings in independent
subjects, proved to be an efficient strategy for individual gene
discovery in abnormal neurodevelopment. As this approach
begins with sequence resolution of individual BCAs, it is not
subject to notable limitations of other de novo mutation studies
that rely purely on CNVs or on exome sequencing (i.e., primarily
identification of large multigene regions in the former and failure
to assess most noncoding sequence in the latter) and therefore
provides aneffective complement to theseapproaches. The yield
of this study is considerable; 22 novel loci are disrupted by
BCAs and 14 loci are supported from secondary analyses
either by a statistical enrichment of CNV burden or disruption in
multiple cases and absence of dosage alterations in controls,with several additional genes and sequences whose potential
for contribution merits further examination. These findings not
only extend specific knowledge of neurodevelopmental genes
implicated by microdeletion syndromes, GWA, CNV, and exome
sequencing studies but also reveal entirely unsuspected genes
in ASD and NDD. This work also presents direct evidence for
a complex genetic architecture that connects neurodevelop-
mental and adult-onset psychiatric disorders by implicating
robustly associated schizophrenia loci as contributors to neuro-
developmental abnormalities.
Our analyses were based upon the premise that alone, a de
novo BCA disruption in a single case, CNVs spanning a given
locus, or the presence of a de novo mutation within the coding
region of an interesting biological candidate does not by itself
represent compelling evidence that a gene contributes to neuro-
development. Instead, we sought convergent genomic evidence
combining disruption by a de novo BCA (or in two subjects a
BCA that cosegregated with the phenotype) with association
by CNV or mutation in independent and similarly affected cases,
followed by comparison with risk loci from GWAS studies. The
strength of evidence varied between loci, as shown in Table 1
and Table S2. In some instances, genes were statistically sup-
ported by secondary CNV analyses, in others, the statistical
support was inconclusive, and in several the CNV data do not
nominate the locus as an NDD candidate (e.g., ZBTB20; seeCell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc. 533
Table 1, Table S2, and Table S3). Additionally, like any genetic
study, we cannot discount a potential contribution from altered
expression of other genes at a distance from the site of the
disruption. Although such an effect could result from the trans-
position of functional elements, the comprehensive testing of
this possibility is problematic because it could involve dysregu-
lation that is tissue-specific, that occurs due to the potentially
altered nuclear organization of the rearranged chromosomes,
or that is a secondary physiological consequence of the primary
gene disruption. Nonetheless, secondary CNV analyses from
independent NDD cases indicate a profound collective contribu-
tion of the disrupted genes on neurodevelopment. Simulations
and subset analyses to evaluate empirical significance estab-
lished that the increased CNV burden of the loci disrupted by
BCAs was robust; unusually specific to neurodevelopmental
disorders compared to other phenotypic presentations referred
for molecular diagnostic testing; and not driven by any single
gene, individual disruption category, cluster of symptoms, or
discrete diagnostic category. Rather, it was an accumulation of
risk factors from all four categories that collectively contributed
to the significant burden observed (see Supplemental Informa-
tion). For some genes, developmental abnormalities were pre-
dominantly associated with dosage alteration in only one
direction, whereas for others the increased CNV burden involved
both deletions and duplications. These data illustrate the imma-
ture state of annotation of the human genome with respect to
dosage sensitivity and to prediction of phenotypic outcomes
from genetic lesions, a limitation that may be alleviated at least
in part by the growing capacity to sequence BCAs in a relatively
high-throughput manner.
A surprising number of genes previously associated with
adolescent- or adult-onset psychiatric disorders were disrupted
in children with autism and NDD in this study. The concept of
schizophrenia as a neurodevelopmental disorder has long
been proposed (Murray and Lewis, 1987; Weinberger, 1986),
and a growing consensus in the recent literature suggests that
there are shared risk factors across what are viewed clinically
as distinct phenotypic classifications, although few of these
have been described at the individual gene level (Owen et al.,
2011). Our study supports a shared genetic etiology for at least
a portion of the phenotypic spectrum of schizophrenia, autism,
and the neurodevelopmental abnormalities studied here. We
find unambiguous gene disruption by BCAs in ASD and NDD
subjects, coupled with an increased CNV burden and a substan-
tial overrepresentation of polygenic risk compared to null
expectations from GWAS of schizophrenia. Individual genes
may thus show a differential risk depending on the nature of
the genetic lesion, with heterozygous inactivation from BCA,
CNV, or deactivating point mutation being a relatively penetrant
contributor to ASD or NDD, whereas subtle effects from
common variants contribute to later-onset disorders. However,
contrary to this simple hypothesis, we were surprised to find
persistent enrichment of these genes also among common
variant associations from autism GWAS studies, suggesting
that even subtle perturbation of genes important in normal
human development can contribute to abnormal outcomes
across the lifespan, presumably in interaction with other genetic
and environmental influences.534 Cell 149, 525–537, April 27, 2012 ª2012 Elsevier Inc.This initial sequence-based delineation of a large collection of
subjects harboring chromosomal aberrations in autism and
related neurodevelopmental disorders establishes an approach
that can be exploited for efficient discovery of individual genetic
factors contributing to otherwise complex disorders. Each
individual gene identified provides a new, specific hypothesis
concerning the disease to be tested with further genetic and
biological study. If supported, each then represents a foundation
for investigations into the role that the biochemical activity and
regulation of its product play in pathogenesis and into the poten-
tial for treatment through their manipulation. Ultimately, such
data will also provide invaluable annotation of the human
genome and profoundly impact the clinical interpretation of
genomic events in subjects referred to diagnostic laboratories
for autism and other developmental abnormalities.
EXPERIMENTAL PROCEDURES
Patients
Subjects were obtained from the Developmental Genome Anatomy Project
(DGAP) (Higgins et al., 2008), the Autism Consortium of Boston, the Center
for Human Genetic Research (CHGR) Neurodevelopmental Repository, and
the Autism Genome Resource Exchange (AGRE). These studies were
approved by the institutional review board of Partners HealthCare System.
Clinical information was obtained by direct questionnaires, medical records,
or structured clinical interviews (see Data S1: Phenotypic and Sequencing
Information on Individual Patients).
Sequencing
Sequencing was performed on the Illumina platform (Illumina). Libraries were
created by four different methods optimized for delineating BCAs, including
(1) Illumina standard insert paired-end sequencing, (2) Illumina mate-pair
sequencing (long 2,000–4,000 bp inserts), (3) our customized jumping libraries
(long 3,000–4,500 bp inserts), and (4) our capture of breakpoints method
(CapBP) for rearrangements previously localized (see Supplemental Informa-
tion with complete protocols in Talkowski et al. [2011a]). Interestingly, some
rearrangements proved to be far more complex than suspected by karyotyp-
ing, and in at least two subjects this complexity represented balanced
germline chromothripsis similar to but distinct from previously described
events in cancer cells (DGAP127 and DGAP203; see Table S4 and (Chiang
et al., 2012)). In complex rearrangements where more than two genes were
disrupted by BCA breakpoints, we conservatively excluded these cases
from interpretation in our secondary CNV/GWAS analyses.
Bioinformatics
Sequencing reads were aligned via publicly available alignment programs and
custom scripts, followed by processing of BAM files with a C++ program,
Bamstat, to tabulate mapping statistics and output lists of anomalous
read-pairs (defined as having ends that map to two different chromosomes,
having an abnormal insert size, and/or unexpected strand orientations)
(Talkowski et al., 2011a). Anomalous pairs were clustered by their mapped
mates with a program that performs a single-linkage clustering of paired reads
if corresponding ends map within a specified distance. All junction fragments
predicted from paired-end sequencing were PCR amplified from genomic
DNA, independent of the libraries and sequencing reads, and all breakpoints
presented in this study were confirmed by capillary sequencing (Table S1
and also Table S5).
Evaluation of CNVs in Independent Subjects
Complete details on the CNV data, statistical analyses, and simulations to
determine empirical significance are fully described in Supplemental Informa-
tion. We compiled CNV data from 33,573 cases from molecular diagnostic
laboratories of Signature Genomic Laboratories (SG) and Children’s Hospital
Boston (CHB) analyzed by oligonucleotide aCGH. A subset of the SG data
was included in a recent CNV study (Cooper et al., 2011). We fully annotated
both data sets and collapsed all subjects with an indication for study (but
without additional clinical information to verify a specific diagnosis) of autism,
ASD, or a related neurodevelopmental abnormality into a combined NDD
cohort (19,556 cases) and those for which the clinical indication did not
indicate an NDD (14,017 cases). Control data were obtained across multiple
published resources as described in the Supplemental Information (n =
13,991 independent controls). Only 6,239 controls were analyzed for CNVs
on the X chromosome, and this reduced comparison group was used for
analyses of CDKL5. The resolution between the clinical aCGH and higher-
resolution control SNP microarrays varied extensively. To overcome this
disparity but retain the native resolution of each individual array platform, we
analyzed all CNVs that disrupted any documented coding or noncoding
exon from all transcripts available from multiple database sources (Table
S1). Notably, post hoc analyses reveal that a size filter of 100 kb, or the reso-
lution of the most sparse control arrays, would have resulted in an almost
identical CNV burden test to our exon disruption model (p = 1.18 3 1047),
but would have omitted high-confidence CNV calls in controls that could point
toward reduced penetrance or nonsignificant loci in this study such as
ZBTB20. Empirical significance was established by simulations performed in
MATLAB (Mathworks) with custom scripts with all methods and findings
described in the Supplemental Information. In brief, 1 million gene sets of 33
loci were randomly selected from the genome, and case-control CNV burden
tests were performed for each random gene set. These same analyses were
performed for NDD cases compared to all other cases in the molecular diag-
nostic cohort. Neither simulation detected a random gene set exceeding the
significance of the experimental gene set. Another set of experiments per-
formed subset analyses, randomly selecting up to 1,000 gene sets of each
possible number of k genes from the experimental gene set of 33 loci, ranging
from k = 5 to k = 33, finding a minimum of 90.5% of all subsets at a level as low
as k = 5 exceededmultiple testing correction and 100% of the 1,000 gene sets
to be significant at k > 13 (see Supplemental Information).
Genome-wide Association Studies
We performed gene-set enrichment analysis from GWAS data by using pub-
lishedmethods (Rossin et al., 2011) on a recentmeta-analysis of schizophrenia
(Ripke et al., 2011) and two GWASs of autism (Weiss et al., 2009; Wang et al.,
2009). Briefly, linkage disequilibrium blocks across the genome are scored
with the maximum Z score achieved in the block. That score is corrected for
the number of tests across the block via linear regression and the residuals
are then used as the new, corrected score for each block. Genes nominate
scores based upon the unique set of blocks they overlap, and the nominated
scores are compared to background scores from all genes in the genome via
a one-tailed rank-sum test.
Network Analysis
A qualitative assessment of interacting genes and complexes for each of the
genes in which functional information was available (little data existed for
some of the novel genes) was initially performed with Natural Language Pro-
cessing (NLP) from published abstracts (see Supplemental Information).
Secondary analyses of GO and Kyoto Encyclopedia Of Genes And Genomes
(KEGG) enrichments were then performed followed by quantitative network
building of first- and second-order interactions of the set of proteins coded
by the genes disrupted by BCAs. The significance of these networks was
determined by permutation testing (Supplemental Information).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and five tables and can be found with this article online at
doi:10.1016/j.cell.2012.03.028.
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